Head Of Australia’s Bone Medical Ousted After Two Years
This article was originally published in PharmAsia News
Executive SummaryAustralia's Bone Medical biopharmaceutical company is losing its managing director of the past two years. Troels Jordansen lost his job in a restructuring of the company's board of directors, to be replaced soon by an unnamed person from the United States. Bone Medical, which concentrates on breakthrough treatments for bone and joint degeneration and related diseases, reported having less than $124,000 in cash at the end of the March quarter. (Click here for more
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.